NCT00150176View on ClinicalTrials.gov

To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)

PHASE3CompletedINTERVENTIONAL
Enrollment

831

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

June 30, 2008

Study Completion Date

July 31, 2008

Conditions
Schizophrenia
Interventions
DRUG

Asenapine - Open Label

Open Label Phase: All subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1).

DRUG

Placebo - Double Blind

Double Blind Phase: Following Open Label Phase, matching placebo sublingual twice daily for 26 weeks.

DRUG

Asenapine - Double Blind

Double Blind Phase: Following the Open Label Phase, asenapine 5 or 10 mg sublingual twice daily for 26 weeks.

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00150176 - To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770) | Biotech Hunter | Biotech Hunter